Top Institutions in Neuropharmacology and Motion Sickness Treatment
Leading institutions in neuropharmacology and clinical research on motion sickness utilize advanced clinical trials, pharmacodynamic studies, and translational research to develop and validate novel antiemetic therapies targeting neurokinin-1 receptors and related pathways.
-
#100
Johns Hopkins University
Baltimore, MD
Johns Hopkins leads in neuropharmacology research and has extensive experience in clinical trials for gastrointestinal and neurogenic disorders, including nausea and vomiting syndromes.
Key Differentiators
- Neuropharmacology
- Gastroenterology
- Clinical Trials
-
#92
Mayo Clinic
Rochester, MN
Mayo Clinic has a robust clinical research infrastructure and expertise in motion sickness and related neurogastroenterology disorders, contributing to advances in antiemetic drug development.
Key Differentiators
- Neurology
- Gastroenterology
- Clinical Pharmacology
-
#88
Massachusetts General Hospital
Boston, MA
MGH is a leader in neuroscience and pharmacology research, with significant contributions to understanding the neurochemical basis of nausea and the development of targeted therapies.
Key Differentiators
- Neuroscience
- Pharmacology
- Clinical Research
-
#85
University of California, San Francisco (UCSF)
San Francisco, CA
UCSF has a strong focus on neuropharmacology and clinical research in gastrointestinal disorders, including motion sickness, with expertise in receptor-targeted drug development.
Key Differentiators
- Neuropharmacology
- Clinical Trials
- Gastroenterology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
